1. PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2022. PubChem Compound Summary for CID 3463, Gemfibrozil. https://pubchem.ncbi.nlm.nih.gov/compound/Gemfibrozil
4. Roy A et Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 2009; 31(3): 339–351. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772998
5. Kim K, Kleinman HK, Lee HJ, Pahan K. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017; 12: 113. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474050
6. Cunningham ML, Collins BJ, Hejtmancik MR, et al. Effects of the PPAR Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. PPAR Research, vol. 2010, Article ID 681963, 14 pages, 2010. https://doi.org/10.1155/2010/681963.
7. Wiggins BS, Saseen JJ, Morris PB. Gemfibrozil in Combination with Statins-Is It Really Contraindicated? Curr Atheroscler Rep. 2016 Apr;18(4):18. https://www.ncbi.nlm.nih.gov/pubmed/26932225
8. Rouini MR, Baluchestani M, Hakemi L. Study of Dose-linearity of Gemfibrozil Pharmacokinetics in Human. International Journal of Pharmacology. 2006;2:75-78.
9. Medscape. Gemfibrozil (Rx). 2022. https://reference.medscape.com/drug/lopid-gemfibrozil-342457#10